EyePoint Inc Dossier
Qualitative Analysis
Business overview
EyePoint, Inc. (formerly known as EyePoint Pharmaceuticals, Inc. until its corporate rebranding in December 2025) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU™ (vorolanib intravitreal insert, formerly EYP-1901), an investigational sustained-delivery tyrosine kinase inhibitor (TKI) designed to address major retinal disease markets, specifically wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing DURAVYU (vorolanib intravitreal insert) through two global, pivotal Phase 3 trials (LUGANO and LUCIA) evaluating a six-month redosing schedule to reduce treatment burden in wet age-related macular degeneration.
Expected impact: Establish DURAVYU as a potential first-in-class and best-in-class sustained delivery therapy for wet AMD, paving the way for an NDA filing.
Evaluating DURAVYU in diabetic macular edema (DME) through two identical Phase 3 trials, COMO and CAPRI, enrolling approximately 480 patients globally to assess non-inferiority against on-label aflibercept.
Expected impact: Expand DURAVYU's target market to include DME, the second largest retinal disease market.
Scaling up operations at the 41,000 square-foot cGMP commercial manufacturing facility in Northbridge, Massachusetts, to support registration batches and prepare for FDA pre-approval inspections.
Expected impact: Ensure commercial supply readiness and satisfy the Chemistry, Manufacturing, and Controls (CMC) requirements for the planned DURAVYU NDA.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Completed the sale of U.S. and global commercial rights (excluding certain Asian territories) for YUTIQ in May 2023, transforming EyePoint into a pure-play clinical development company.
Terms: EyePoint received a $75 million upfront cash payment, $7.5 million in equal quarterly installments in 2024, and is entitled to receive low-to-mid double-digit royalties on U.S. net sales of YUTIQ and ILUVIEN above defined thresholds from 2025 to 2028.
Exclusive license for vorolanib (the active TKI in DURAVYU) for localized ophthalmic delivery. Betta retains development and commercialization rights in Greater China, while EyePoint holds exclusive rights for the rest of the world.
Terms: Expanded in May 2022 to grant Betta exclusive rights in Mainland China, Hong Kong, Macau, and Taiwan, while amending the Equinox agreement to secure EyePoint's global ophthalmic rights outside of those territories.